Prelude Therapeutics Incorporated
200 Powder Mill Road
Wilmington, Delaware 19803
January 4, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
| Attention: |
Deanna Virginio | |
| Re: | Prelude Therapeutics Incorporated Registration Statement on Form S-1 (File No. 333-251874) originally filed January 4, 2021. | |
Requested Date: January 6, 2021
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
Prelude Therapeutics Incorporated (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Forbess at (415) 875-2420.
* * *
| Sincerely, | ||
| PRELUDE THERAPEUTICS INCORPORATED | ||
| By: | /s/ Krishna Vaddi | |
| Krishna Vaddi, Ph.D. | ||
| Chief Executive Officer | ||
| cc: | Brian Piper, Chief Financial Officer |
Prelude Therapeutics Incorporated
Effie Toshav, Esq.
Robert A. Freedman, Esq.
Fenwick & West LLP